MXPA05010196A - Formulations comprising an active ingredient and cocoa powder and use thereof. - Google Patents

Formulations comprising an active ingredient and cocoa powder and use thereof.

Info

Publication number
MXPA05010196A
MXPA05010196A MXPA05010196A MXPA05010196A MXPA05010196A MX PA05010196 A MXPA05010196 A MX PA05010196A MX PA05010196 A MXPA05010196 A MX PA05010196A MX PA05010196 A MXPA05010196 A MX PA05010196A MX PA05010196 A MXPA05010196 A MX PA05010196A
Authority
MX
Mexico
Prior art keywords
cocoa powder
formulations
active ingredient
formulation
apis
Prior art date
Application number
MXPA05010196A
Other languages
Spanish (es)
Inventor
Alice C Martino
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of MXPA05010196A publication Critical patent/MXPA05010196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.
MXPA05010196A 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof. MXPA05010196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (en) 2003-03-26 2003-03-26 New formulations and use therof
PCT/IB2004/000860 WO2004084865A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof

Publications (1)

Publication Number Publication Date
MXPA05010196A true MXPA05010196A (en) 2005-11-08

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010196A MXPA05010196A (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof.

Country Status (13)

Country Link
EP (1) EP1605921A1 (en)
JP (2) JP2006521348A (en)
CN (1) CN1764440A (en)
AR (1) AR043772A1 (en)
AU (1) AU2004224557B2 (en)
BR (1) BRPI0408655A (en)
CA (1) CA2519155A1 (en)
CL (1) CL2004000564A1 (en)
MX (1) MXPA05010196A (en)
SE (1) SE0300831D0 (en)
TW (1) TW200503782A (en)
WO (1) WO2004084865A1 (en)
ZA (1) ZA200507719B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2004512354A (en) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． Hydrocodone controlled release formulation
JP5558712B2 (en) * 2005-08-02 2014-07-23 ドロサファーム アクチェンゲゼルシャフト Pharmaceutical composition comprising indomethacin and / or acemetacin
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR101660666B1 (en) 2007-06-13 2016-09-27 오츠카 세이야쿠 가부시키가이샤 Equol-containing food
WO2009070978A1 (en) * 2007-11-22 2009-06-11 Yu He An oral cavity rapid release of the health products and its preparation method
CN101444273B (en) * 2007-11-22 2013-04-24 何煜 Health product oral fast-release preparation and production method thereof
CN101439053A (en) * 2007-11-22 2009-05-27 何煜 Chinese medicine rapid-release preparation for oral cavity and method for producing the same
CA2761538A1 (en) * 2009-05-20 2010-12-23 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
EP2964243B1 (en) 2013-03-06 2022-11-23 Capsugel Belgium NV Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (en) * 2013-11-01 2015-11-25 阳波 Caf metronidazole chewing gum
US20170112762A1 (en) * 2014-06-10 2017-04-27 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
EP3226845A1 (en) 2014-12-04 2017-10-11 Capsugel Belgium NV Lipid multiparticulate formulations
JP6334482B2 (en) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 Solid agent and production method thereof
CA2984917C (en) * 2015-12-09 2023-09-26 Poviva Tea, Llc Stable ready-to-drink beverage compositions comprising lipophilic active agents
CA3176596A1 (en) * 2015-12-09 2017-06-15 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
WO2018090096A1 (en) 2016-11-18 2018-05-24 The University Of Western Australia Taste masking product
US20210000963A1 (en) * 2018-03-01 2021-01-07 Lts Lohmann Therapie-Systeme Ag Oral dosage form containing theobromine-free cocoa
CN109053718B (en) * 2018-08-09 2022-06-03 天津理工大学 Rosiglitazone saccharin salt and preparation method thereof
CN111729087A (en) * 2020-07-24 2020-10-02 成都大学 Lipid modifier of selective beta 2 receptor agonist and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (en) * 1994-03-17 1996-10-18 Hi Pharmtech Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate.
SE9803986D0 (en) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (en) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk Intraoral medicine
JP2001114668A (en) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd Chocolate preparation
JP2002193839A (en) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd Cocoa pharmaceutical preparation
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (en) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
JP2006521348A (en) 2006-09-21
ZA200507719B (en) 2007-09-26
CA2519155A1 (en) 2004-10-07
BRPI0408655A (en) 2006-03-28
JP2011079841A (en) 2011-04-21
CN1764440A (en) 2006-04-26
AU2004224557B2 (en) 2009-06-18
AU2004224557A1 (en) 2004-10-07
AR043772A1 (en) 2005-08-10
CL2004000564A1 (en) 2005-02-04
TW200503782A (en) 2005-02-01
SE0300831D0 (en) 2003-03-26
EP1605921A1 (en) 2005-12-21
WO2004084865A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
MXPA05010196A (en) Formulations comprising an active ingredient and cocoa powder and use thereof.
WO2004112711A3 (en) Oral extended-release composition
NO993520L (en) Dosage forms and methods for better erectile dysfunction
HUP0203168A2 (en) Compositions for mucosal delivery
MXPA04007980A (en) Taste-masked film-type or wafer-type medicinal preparation.
WO2004043474A3 (en) Use of one or more elements from the group containing yttrium, neodymium and zirconium
WO2004058217A3 (en) Water-soluble film for oral use
HUP0301349A2 (en) Formulations for il-11
BG108516A (en) Pharmaceutical formulation
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA03010628A (en) Vitamin d analogues.
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
EP1603595A4 (en) Pharmaceutical composition for treatment of drug dependence
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2002360975A1 (en) Disinfection agent for suction systems used in the field of medicine
CA2461757A1 (en) Nicotine formulations comprising chocolate and use thereof
WO2004052331A3 (en) Use of a cotton honeydew extract as active ingredient in or for preparing a cosmetic and/or pharmaceutical composition
WO2002041875A3 (en) Method for producing readily soluble medicament formulations and corresponding formulations
SE0300830D0 (en) New formulations and use thereof
ECSP045056A (en) VALDECOXIB INTRAORAL DISGREGATION COMPOSITIONS PREPARED BY A SPRAY DESIRATION PROCEDURE

Legal Events

Date Code Title Description
GB Transfer or assignment